RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
+63.95%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$4.18B
AUM Growth
+$4.18B
(+40%)
Cap. Flow
+$288M
Cap. Flow
% of AUM
6.88%
Top 10 Holdings %
Top 10 Hldgs %
48.69%
Holding
89
New
15
Increased
28
Reduced
14
Closed
24
Top Buys
| 1 |
Biogen
BIIB
|
$136M |
| 2 |
PRNB
Principia Biopharma Inc. Common Stock
PRNB
|
$106M |
| 3 |
Aprea Therapeutics
APRE
|
$104M |
| 4 |
Boston Scientific
BSX
|
$73.8M |
| 5 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
$63.9M |
Top Sells
| 1 |
ALDR
Alder Biopharmaceuticals, Inc.
ALDR
|
$155M |
| 2 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
$139M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$114M |
| 4 |
CELG
Celgene Corp
CELG
|
$55.9M |
| 5 |
WMGI
Wright Medical Group Inc
WMGI
|
$49.6M |
Sector Composition
| 1 | Healthcare | 98.47% |
| 2 | Industrials | 0.33% |
| 3 | Technology | 0% |
| 4 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
DCPH
1
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $293M | 7.01% | 4,709,498 -71,400 | -1% | -$4.44M |
|
|
ALLK
2
DELISTED
Allakos
ALLK
| $289M | 6.92% | 3,033,526 -43,602 | -1% | -$4.16M |
|
3
Amicus Therapeutics
FOLD
$2.34B
| $246M | 5.87% | 25,209,964 +2,419,830 | +11% | +$23.6M |
|
4
Fate Therapeutics
FATE
$120M
| $220M | 5.25% | 11,216,809 | – | – |
|
|
EPZM
5
DELISTED
Epizyme, Inc
EPZM
| $215M | 5.15% | 8,746,033 +109,100 | +1% | +$2.68M |
|
6
argenx
ARGX
$43.6B
| $185M | 4.43% | 1,153,232 +72,800 | +7% | +$11.7M |
|
7
uniQure
QURE
$896M
| $183M | 4.38% | 2,553,325 +143,200 | +6% | +$10.3M |
|
|
PRNB
8
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $149M | 3.57% | 2,722,388 +1,932,382 | +245% | +$106M |
|
|
9
Biogen
BIIB
$19.4B
| $136M | 3.25% | +457,500 | New | +$136M |
|
|
IGMS
10
DELISTED
IGM Biosciences
IGMS
| $120M | 2.87% | 3,144,000 | – | – |
|
11
Bristol-Myers Squibb
BMY
$96B
| $116M | 2.76% | 1,800,800 -451,800 | -20% | -$29M |
|
|
NVRO
12
DELISTED
NEVRO CORP.
NVRO
| $110M | 2.64% | 939,164 +295,300 | +46% | +$34.7M |
|
|
FTSV
13
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| $109M | 2.61% | 2,770,842 +1,143,344 | +70% | +$45M |
|
|
14
Aprea Therapeutics
APRE
$9.09M
| $104M | 2.49% | +2,268,718 | New | +$104M |
|
15
Regenxbio
RGNX
$451M
| $103M | 2.46% | 2,508,386 +145,900 | +6% | +$5.98M |
|
16
Centene
CNC
$14.3B
| $97.6M | 2.33% | 1,552,598 +742,100 | +92% | +$46.7M |
|
|
TCDA
17
DELISTED
Tricida, Inc. Common Stock
TCDA
| $80.4M | 1.92% | 2,129,100 +51,400 | +2% | +$1.94M |
|
18
Atara Biotherapeutics
ATRA
$84.6M
| $76.6M | 1.83% | 4,648,570 +128,853 | +3% | +$2.12M |
|
|
IMGN
19
DELISTED
Immunogen Inc
IMGN
| $74.7M | 1.79% | 14,639,960 +23,400 | +0.2% | +$119K |
|
|
20
Boston Scientific
BSX
$156B
| $73.8M | 1.76% | +1,631,200 | New | +$73.8M |
|
21
Tandem Diabetes Care
TNDM
$845M
| $69.9M | 1.67% | 1,172,232 +11,831 | +1% | +$705K |
|
|
MNTA
22
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $63.9M | 1.53% | +3,237,700 | New | +$63.9M |
|
23
Krystal Biotech
KRYS
$4.27B
| $60.4M | 1.44% | 1,090,200 +11,900 | +1% | +$659K |
|
24
UnitedHealth
UNH
$281B
| $59.7M | 1.43% | 203,100 +202,129 | +20,817% | +$59.4M |
|
25
Novartis
NVS
$245B
| $54.3M | 1.3% | +573,100 | New | +$54.3M |
|